MX2015005148A - Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r. - Google Patents

Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r.

Info

Publication number
MX2015005148A
MX2015005148A MX2015005148A MX2015005148A MX2015005148A MX 2015005148 A MX2015005148 A MX 2015005148A MX 2015005148 A MX2015005148 A MX 2015005148A MX 2015005148 A MX2015005148 A MX 2015005148A MX 2015005148 A MX2015005148 A MX 2015005148A
Authority
MX
Mexico
Prior art keywords
alpha
forms
complexes
covalently
soluble forms
Prior art date
Application number
MX2015005148A
Other languages
English (en)
Other versions
MX365527B (es
Inventor
John N Vournakis
Barbara K Felber
Sergio Finkielszttein
George N Pavlakis
Original Assignee
Admune Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50545467&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015005148(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Admune Therapeutics Llc filed Critical Admune Therapeutics Llc
Publication of MX2015005148A publication Critical patent/MX2015005148A/es
Publication of MX365527B publication Critical patent/MX365527B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En un aspecto, en la presente se describen los esquemas cíclicos para la administración de complejos que contienen interleucina-15 ("IL-15") unida en forma covalente o no covalente al receptor de IL-15 alfa ("IL-15Ra") a un paciente con el fin de mejorar la función inmunitaria mediada por IL-15. En un aspecto específico, los esquemas de administración cíclicos son útiles para la prevención, tratamiento y/o manejo de trastornos en los que es benéfica la mejoría de la función mediada por IL-15 como el cáncer, enfermedades infecciosas, deficiencias inmunológicas y linfopenia. También se describen en la presente las formas solubles, purificadas de IL-15Ra, las células que expresan en forma recombinante las formas solubles de IL-15Ra, y las composiciones que contienen complejos de IL-15 unidos en forma covalente o no covalente a las formas solubles de IL-15Ra. Además se describen en la presente las células hospederas que expresan de manera recombinante los derivados de IL-15-Ra que comprenden una mutación o deleción en el sitio de desdoblamiento del dominio extracelular, que incluyen los derivados de IR-15Ra que comprenden el dominio extracelular de IL-15Ra y un domino transmembranal de una molécula heteróloga.
MX2015005148A 2012-10-24 2013-10-23 Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r. MX365527B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718169P 2012-10-24 2012-10-24
US201361820035P 2013-05-06 2013-05-06
PCT/US2013/066424 WO2014066527A2 (en) 2012-10-24 2013-10-23 Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes

Publications (2)

Publication Number Publication Date
MX2015005148A true MX2015005148A (es) 2015-09-25
MX365527B MX365527B (es) 2019-06-06

Family

ID=50545467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005148A MX365527B (es) 2012-10-24 2013-10-23 Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r.

Country Status (11)

Country Link
US (2) US20150359853A1 (es)
EP (1) EP2911684B1 (es)
JP (1) JP6359019B2 (es)
AU (1) AU2013334610B2 (es)
CA (1) CA2888896A1 (es)
ES (1) ES2747997T3 (es)
HK (1) HK1211467A1 (es)
IL (1) IL238476B (es)
MX (1) MX365527B (es)
NZ (1) NZ630790A (es)
WO (1) WO2014066527A2 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2529747T3 (pl) 2005-12-02 2018-08-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentuące nienatywne białka powierzchniowe i zastosowania tych wirusów
DK2769984T3 (en) 2007-05-11 2017-10-16 Altor Bioscience Corp Fusion molecules and IL-15 variants
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
PT2918607T (pt) 2010-09-21 2018-01-11 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
SG11201507412SA (en) 2013-03-14 2015-10-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
KR20150145260A (ko) 2013-04-19 2015-12-29 싸이튠 파마 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료
BR112016002614B8 (pt) * 2013-08-08 2023-10-03 Hopitaux Paris Assist Publique Imunocitoquina e composição farmacêutica
KR20220148304A (ko) * 2013-08-08 2022-11-04 싸이튠 파마 병용 약학 조성물
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR102503476B1 (ko) 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
WO2016018920A1 (en) * 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
KR102609197B1 (ko) * 2014-12-19 2023-12-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인터류킨 15 단백질 복합체 및 그의 용도
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
AU2016333873A1 (en) 2015-10-06 2018-05-17 The Wistar Institute Of Anatomy And Biology Methods and compositions for treatment of metastatic and refractory cancers and tumors
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017173367A2 (en) 2016-03-31 2017-10-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extracellular vesicles, methods of making them, and methods of reducing liver uptake of extracellular vesicles
EP3439688A4 (en) * 2016-04-04 2020-05-27 The Regents of the University of California COMPOSITIONS AND METHODS IN CONNECTION WITH POLYCYTOTOXIC T CELLS
WO2017177063A1 (en) 2016-04-06 2017-10-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of heterodimeric il-15 in adoptive cell transfer
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AU2017268399B2 (en) 2016-05-18 2023-01-12 Modernatx, Inc. mRNA combination therapy for the treatment of cancer
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2018013855A2 (en) * 2016-07-14 2018-01-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines
WO2018067825A1 (en) * 2016-10-05 2018-04-12 University Of Central Florida Research Foundation, Inc. Methods and compositions related to nk cell and anti-pdl1 cancer therapies
WO2018075989A1 (en) 2016-10-21 2018-04-26 Altor Bioscience Corporation Multimeric il-15-based molecules
CN110177568A (zh) * 2017-01-20 2019-08-27 诺华股份有限公司 用于治疗癌症的组合疗法
CN110337305A (zh) * 2017-02-28 2019-10-15 赛诺菲 治疗性rna
US20190048055A1 (en) * 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018217203A1 (en) * 2017-05-25 2018-11-29 Oreilly Richard John Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
US20190048072A1 (en) 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
EA202090104A1 (ru) 2017-06-22 2020-04-09 Новартис Аг Молекулы антител к cd73 и пути их применения
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3645037A1 (en) 2017-06-27 2020-05-06 Novartis AG Dosage regimens for anti-tim-3 antibodies and uses thereof
EP3655023A1 (en) 2017-07-20 2020-05-27 Novartis AG Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019019998A1 (zh) * 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 一种il-15蛋白复合物药物组合物及其用途
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
CN111432838A (zh) 2017-12-01 2020-07-17 美勒斯公司 使用双特异性抗体和il-15进行联合治疗
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CU20200089A7 (es) 2018-06-01 2021-07-02 Novartis Ag Moléculas de unión contra bcma
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
EP3810171A4 (en) * 2018-06-22 2022-04-06 Cugene Inc. NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOF
TWI809130B (zh) * 2018-06-22 2023-07-21 美商凱特製藥公司 嵌合跨膜蛋白及其用途
CA3102823A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
KR20210107730A (ko) 2018-12-21 2021-09-01 노파르티스 아게 골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
JP2022514087A (ja) 2018-12-21 2022-02-09 ノバルティス アーゲー ＩＬ－１β結合抗体の使用
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
KR20220012296A (ko) 2019-05-20 2022-02-03 싸이튠 파마 암 또는 감염성 질환 치료를 위한 IL-2/IL-15Rβγ 작용제 투여 요법
CN114341189A (zh) * 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
WO2021079188A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
CA3164337A1 (en) * 2019-12-13 2021-06-17 Cugene Inc. Novel interleukin-15 (il-15) fusion proteins and uses thereof
US20210188933A1 (en) * 2019-12-18 2021-06-24 Nantcell, Inc Methods of treating pancytopenia
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
US20210244821A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
AU2021297099A1 (en) 2020-06-23 2023-01-05 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
AU2021367887A1 (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
CA3195276A1 (en) 2020-10-26 2022-05-05 Stefano FERRARA Il-2/il-15rb?? agonist for treating non-melanoma skin cancer
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CA3220418A1 (en) 2021-06-23 2022-12-29 Guy Luc Michel De Martynoff Interleukin 15 variants
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024040132A2 (en) 2022-08-16 2024-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Synergistic interactions for improved cancer treatment
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444713A1 (fr) 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4135070C1 (es) 1991-10-24 1993-05-19 Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5591630A (en) 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
EP3263581B1 (en) * 2005-05-17 2020-11-04 University of Connecticut Compositions and methods for immunomodulation in an organism
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US8021668B2 (en) 2005-12-12 2011-09-20 Immune Disease Institute, Inc. Integrin alpha L I domain mutants with increased binding affinity
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
NZ596494A (en) * 2006-01-13 2013-07-26 Us Gov Nat Inst Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
DK2769984T3 (en) 2007-05-11 2017-10-16 Altor Bioscience Corp Fusion molecules and IL-15 variants
EP2724728B1 (en) * 2007-06-27 2018-10-17 The United States of America, as Represented by The Secretary, Department of Health and Human Services Complexes of il-15 and il-15r alpha and uses thereof
CN102099221B (zh) 2008-08-22 2014-01-29 麦格纳座椅公司 具有减小空转的盘形调角器
EP3135294B1 (en) * 2009-08-14 2020-06-03 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Use of il-15-il-15 receptor heterodimers to treat lymphopenia
PT2918607T (pt) 2010-09-21 2018-01-11 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas

Also Published As

Publication number Publication date
US20190209653A1 (en) 2019-07-11
EP2911684B1 (en) 2019-06-19
EP2911684A4 (en) 2016-08-10
JP6359019B2 (ja) 2018-07-18
MX365527B (es) 2019-06-06
ES2747997T3 (es) 2020-03-12
CA2888896A1 (en) 2014-05-01
HK1211467A1 (en) 2016-05-27
AU2013334610A1 (en) 2015-05-14
WO2014066527A3 (en) 2014-07-03
AU2013334610B2 (en) 2018-09-13
JP2015536935A (ja) 2015-12-24
IL238476A0 (en) 2015-06-30
EP2911684A2 (en) 2015-09-02
WO2014066527A2 (en) 2014-05-01
NZ630790A (en) 2016-11-25
US20150359853A1 (en) 2015-12-17
IL238476B (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2015005148A (es) Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r.
PH12016500040A1 (en) Pcsk9 vaccine
SG178954A1 (en) Immunogenic compositions including tlr activity modulators
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MX2012002654A (es) Compuestos y composiciones como moduladores de la actividad de tlr.
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
WO2016018920A8 (en) Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
MX2016003456A (es) Compuestos aminopirimidina sustituidos y metodos de uso.
MY159208A (en) A novel formulation of indomethacin
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
AU2010329805B2 (en) New conjugates and compositions for immunotherapy and anti-tumoral treatment
AU2016219650A1 (en) Compositions and methods for extended therapy with aminopyridines
PH12016500746A1 (en) A novel formulation of meloxicam
SG10201804305SA (en) Stabilized ophthalmic galactomannan formulations
NZ606768A (en) Pharmaceutical compositions and methods of treatment
PH12014502314B1 (en) Optimised subcutaneous therapeutic agents
IN2015DN03854A (es)
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
NZ610538A (en) Fgfr1 extracellular domain combination therapies
SG10201901391RA (en) Induction of il-12 using immunotherapy
IN2014DN07794A (es)
MX2012006265A (es) Formulaciones disacaridas hipersulfatadas.
MX2013006353A (es) Metodos y composiciones utiles para promover el sueño en animales.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH

FG Grant or registration